Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.1Chloride as the counterion
What ifWhat if chloride balances the charge of the protonated quinazoline compound?
Claim language“a mesylate salt and an esylate salt”
Hydrogen chloride in isopropanol protonates the quinazoline free base and supplies chloride as the counterion. Chloride assay and liquid chromatography establish the counterion-to-compound molar ratio in the recovered solid.
1.1Besylate as the counterion
What ifWhat if benzenesulfonate balances the charge of the protonated quinazoline compound?
Claim language“a mesylate salt and an esylate salt”
Benzenesulfonic acid transfers a proton to the free base in an alcoholic solvent and supplies the benzenesulfonate counterion. Quantitative proton nuclear magnetic resonance measures the counterion-to-compound ratio from resolved aromatic signals.
1.1Bromide as the counterion
What ifWhat if bromide balances the charge of the protonated quinazoline compound?
Claim language“a mesylate salt and an esylate salt”
Hydrobromic acid supplies the proton and bromide when mixed with the free base in aqueous ethanol. Ion chromatography measures bromide in the isolated solid, and liquid chromatography measures the quinazoline compound for calculation of the molar ratio.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Component substitution
Hydrochloride salt of the aminoquinazoline
Chloride replaces the sulfonate counterion while the aminoquinazoline retains its R configuration. A solution of the free base in isopropanol receives one molar proportion of hydrochloric acid, and ethyl acetate serves as the antisolvent for precipitation. Chloride ion chromatography and a quantitative assay of the organic component establish the counterion-to-base ratio of the isolated solid.
Parameter or scale variation
Controlled humidity conditioning of esylate powder
A dynamic vapor sorption balance holds 20 milligrams of esylate powder at 25 degrees Celsius. The chamber steps from 20 to 80 percent relative humidity in 20 percentage point increments, then returns to 20 percent through the same setpoints. The balance advances when the mass change remains below 0.01 percent of the initial sample mass per minute for 10 minutes, or after a two-hour hold. The resulting mass profile records water uptake and release at each setpoint.
Matched sieve fractions for dissolution testing
Dry sieving separates each salt into fractions of 45 to 75 micrometers and 150 to 250 micrometers. Each fraction enters a stirred dissolution vessel at a matched loading of 10 milligrams of free-base content per 100 milliliters of pH 6.8 buffer at 37 degrees Celsius. Liquid chromatography measures dissolved aminoquinazoline in filtered aliquots collected at 1, 5, 15, and 30 minutes, producing a concentration profile for each salt and size fraction.
Combination with existing systems
Mesylate crystallization with inline particle monitoring
A jacketed stirred vessel combines a solution of the mesylate salt with an antisolvent delivered by a metering pump. A focused-beam reflectance probe sits below the liquid surface in the circulating slurry and records chord-length counts during addition and aging. The control system logs the counts alongside temperature and antisolvent flow, and the slurry passes to filtration when the chord-length distribution stabilizes.
Automated or data-driven variant
Automated classification of salt powder patterns
An automated powder diffractometer scans mesylate and esylate samples loaded on a motorized tray. Software subtracts the background, aligns the diffraction angle axis with a calibration sample, and compares each full pattern with stored reference patterns. The software assigns the highest-scoring reference above a threshold established with replicate scans and flags lower-scoring samples for review.
Specific version of a part
Mesylate by antisolvent precipitation
Methanesulfonic acid protonates the free base in ethanol. Gradual addition of ethyl acetate reduces salt solubility, and filtration collects the precipitated mesylate for washing with ethyl acetate and drying under reduced pressure.
Esylate by cooling crystallization
Ethanesulfonic acid combines with the free base in warm isopropanol to form an esylate solution. Controlled cooling generates supersaturation, and filtration separates the resulting crystals from the mother liquor.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
According to the invention there is provided an esylate salt of a compound of formula (I).
A · US 2010/0075955 A1 · ¶ 6
In one embodiment, the present invention provides crystalline salts of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine selected from the group consisting of a besylate, camsylate, esylate, HBr, HCl, mesylate, sulfate, and tosylate salt.
B · US 2014/0038971 A1 · ¶ 3
An empty cell means only that no passage was reproduced there.
Statements in these documents
Whilst the free base of formula (I) is stable when stored at 5° C., samples stored at 40° C./75% relative humidity (open) are observed to deliquesce, become yellow to orange in colour, and show notable decreases in content relative to initial (see Example 1 below).
A · US 2010/0075955 A1 · ¶ 4
It has now surprisingly been found that the compound of formula (I) forms highly crystalline mono esylate (ethanesulphonic acid) salts that are easily isolated from a range of pharmaceutically acceptable solvents and show good thermal stability, low hygroscopicity and high aqueous solubility.
A · US 2010/0075955 A1 · ¶ 5
A need exists for improved therapies for the treatment of diseases relating to diabetes and metabolic disorders.
B · US 2014/0038971 A1 · ¶ 2
In other embodiments, provided are methods for use of a crystalline salt or polymorph described herein for one or more of stimulating insulin production, stimulating glucose-dependent insulin secretion, lowering blood glucose, or lowering blood triglyceride levels, and their uses in the preparation of such medicaments.
B · US 2014/0038971 A1 · ¶ 8
Cite aspatent.fyi, US 2026/0356826 A1, claim 1, first published 2026-11-20T07:31:16-05:00, https://patent.fyi/US20260356826/, SHA-256 aae8353b60abb6fd610620b3b93e87b9e5672016e206785e818b664dc1adffe6